CAMH to use Filament’s natural psilocybin drug candidate for a clinical trial studying treatment-resistant depression VANCOUVER, BC, Nov. 17, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical-stage natural psychedelic drug development company, today announced an agreement with the Centre for Addiction and Mental Health (CAMH)…


Previous articlePT374 – Personalizing Psychedelic Integration
Next articleNuminus to Participate in a Water Tower Research Fireside Chat on Thursday, December 8, 2022